2021
Recipient APOL1 risk alleles associate with death-censored renal allograft survival and rejection episodes
Zhang Z, Sun Z, Fu J, Lin Q, Banu K, Chauhan K, Planoutene M, Wei C, Salem F, Yi Z, Liu R, Cravedi P, Cheng H, Hao K, O’Connell P, Ishibe S, Zhang W, Coca SG, Gibson IW, Colvin RB, He J, Heeger PS, Murphy B, Menon MC. Recipient APOL1 risk alleles associate with death-censored renal allograft survival and rejection episodes. Journal Of Clinical Investigation 2021, 131 PMID: 34499625, PMCID: PMC8592534, DOI: 10.1172/jci146643.Peer-Reviewed Original ResearchConceptsDeath-censored allograft lossAPOL1 risk allelesRisk allelesTransplant outcomesDeath-censored renal allograft survivalRenal allograft survivalChronic allograft rejectionKidney transplant waitlistKidney transplant cohortRisk allele carriersAllograft lossAllograft survivalGraft lossRejection episodesTransplant cohortAllograft rejectionDonor kidneysNative kidneysNK cellsImmunomodulatory roleTransplant waitlistAPOL1 genotypeClinical trialsHealthy controlsHispanic recipients
2015
Renal cancer in kidney transplanted patients
Frascà GM, Sandrini S, Cosmai L, Porta C, Asch W, Santoni M, Salviani C, D’Errico A, Malvi D, Balestra E, Gallieni M. Renal cancer in kidney transplanted patients. Journal Of Nephrology 2015, 28: 659-668. PMID: 26202137, DOI: 10.1007/s40620-015-0219-8.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCalcineurin inhibitorsRenal cancerNative kidneysKidney diseaseWithdrawal of CNIsChronic allograft nephropathyAutosomal dominant polycystic kidney diseaseDominant polycystic kidney diseaseGeneral risk factorsCystic kidney diseasePolycystic kidney diseaseAllograft nephropathyImmunosuppressive therapyRapamycin inhibitorsUltrasound evaluationDialysis treatmentRisk factorsCystic diseaseGeneral populationPatientsMalignancy susceptibilityCancer developmentMammalian targetCancerKidney
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply